
Metformin (1000mg) + Teneligliptin (20mg)
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Medical applications
Joten-M Forte Tablet is a fixed-dose combination medication containing Metformin 1000 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class antihyperglycemic agent, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner. The combination of these two agents provides complementary mechanisms to achieve better glycemic control, reducing fasting and postprandial blood glucose levels. Joten-M Forte is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low unless combined with other antidiabetic agents. Regular monitoring of glycemic parameters and renal function is recommended during therapy to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Joten-M Forte Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Joten-M Forte Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Joten-M Forte Tablet should be used with caution in patients with kidney disease. Dose adjustment of Joten-M Forte Tablet may be needed. Please consult your doctor. Use of Joten-M Forte Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Joten-M Forte Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Joten-M Forte Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Joten-M Forte Tablet

Metformin (1000mg) + Teneligliptin (20mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Medical applications
Joten-M Forte Tablet is a fixed-dose combination medication containing Metformin 1000 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class antihyperglycemic agent, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner. The combination of these two agents provides complementary mechanisms to achieve better glycemic control, reducing fasting and postprandial blood glucose levels. Joten-M Forte is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low unless combined with other antidiabetic agents. Regular monitoring of glycemic parameters and renal function is recommended during therapy to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Joten-M Forte Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Joten-M Forte Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Joten-M Forte Tablet should be used with caution in patients with kidney disease. Dose adjustment of Joten-M Forte Tablet may be needed. Please consult your doctor. Use of Joten-M Forte Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Joten-M Forte Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Joten-M Forte Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Joten-M Forte Tablet













